[关键词]
[摘要]
目的 观察替格瑞洛对氯吡格雷抵抗经皮冠状动脉介入治疗(PCI)术后抗血小板治疗的临床效果。方法 选取2016年6月1日—2016年12月1日廊坊市广阳区管道局总医院心血管内科、急诊科收治的PCI术后冠心病患者100例,按随机数字表法分为观察组与对照组。对照组(50例)采用常规药物治疗,观察组(50例)加用替格瑞洛治疗。比较两组术后血小板聚集率及心脑血管事件发生率。结果 术前,两组血小板聚集率比较无显著差异,术后2 h、1 d、1周,两组血小板聚集率均有所下降(P<0.05);且观察组血小板聚集率明显优于对照组,差异具有统计学意义(P<0.05)。随访期间,观察组心脑血管事件发生率为2.00%(1/50),明显低于对照组的14.00%(7/50),差异具有统计学意义(P<0.05)。结论 替格瑞洛用于氯吡格雷抵抗PCI术后抗血小板治疗,疗效确切,可明显降低术后血小板的聚集率,降低患者心脑血管病的发生率,值得临床推广。
[Key word]
[Abstract]
Objective To observe the clinical effect of clopidogrel on antiplatelet therapy after percutaneous coronary intervention (PCI). Methods In this paper, 100 patients with coronary heart disease were selected from June 1, 2016 to December 1, 2016 in the department of cardiology and emergency department of our hospital, and the random number table method was divided into observation group and control group. The control group (50 cases) were treated with conventional medicine and the observation group (50 cases) was treated with tigrarro. The rate of platelet aggregation and the incidence of cardioascular eents were compared in two groups. Results Preoperative, two groups of platelet aggregation rate was no significant difference, postoperative 2 h, 1 d, 1 w and platelet aggregation rate of observation group was obviously better than the control group (P<0.05), statistically significant difference; During the follow-up period, the incidence of cardioascular eents in the observation group was 2.00% (1/50), which was significantly lower than the control group of 14.00% (7/50), and the difference was statistically significant (P<0.05). Conclusion For Greg los for clopidogrel resistance PCI postoperative antiplatelet therapy, curative effect, can obviously reduce postoperative platelet aggregation rate, reduce the incidence of patients with cardio-cerebral vascular disease, worthy of clinical promotion and use.
[中图分类号]
[基金项目]
廊坊市科学技术研究与发展计划(2016013186)